Diabetic Neuropathy - Pipeline Review, H2 2018

Diabetic Neuropathy - Pipeline Review, H2 2018

Summary


The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2018, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 10, 6, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from  proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  

Introduction 5
Diabetic Neuropathy - Overview 6
Diabetic Neuropathy - Therapeutics Development 7
Diabetic Neuropathy - Therapeutics Assessment 15
Diabetic Neuropathy - Companies Involved in Therapeutics Development 23
Diabetic Neuropathy - Drug Profiles 33
Diabetic Neuropathy - Dormant Projects 100
Diabetic Neuropathy - Discontinued Products 103
Diabetic Neuropathy - Product Development Milestones 104
Appendix 113
  


List Of Tables

Number of Products under Development for Diabetic Neuropathy, H2 2018 11
Number of Products under Development by Companies, H2 2018 13
Number of Products under Development by Universities/Institutes, H2 2018 15
Products under Development by Companies, H2 2018 16
Products under Development by Universities/Institutes, H2 2018 18
Number of Products by Stage and Target, H2 2018 20
Number of Products by Stage and Mechanism of Action, H2 2018 22
Number of Products by Stage and Route of Administration, H2 2018 24
Number of Products by Stage and Molecule Type, H2 2018 26
Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2018 27
Diabetic Neuropathy - Pipeline by Angelini Group, H2 2018 27
Diabetic Neuropathy - Pipeline by Applied Therapeutics Inc, H2 2018 27
Diabetic Neuropathy - Pipeline by Arena Pharmaceuticals Inc, H2 2018 28
Diabetic Neuropathy - Pipeline by Bristol-Myers Squibb Co, H2 2018 29
Diabetic Neuropathy - Pipeline by Celularity Inc, H2 2018 29
Diabetic Neuropathy - Pipeline by Commence Bio Inc, H2 2018 29
Diabetic Neuropathy - Pipeline by Grifols SA, H2 2018 30
Diabetic Neuropathy - Pipeline by Grunenthal GmbH, H2 2018 30
Diabetic Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2018 31
Diabetic Neuropathy - Pipeline by Kineta Inc, H2 2018 31
Diabetic Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2018 31
Diabetic Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018 32
Diabetic Neuropathy - Pipeline by Neuralstem Inc, H2 2018 32
Diabetic Neuropathy - Pipeline by Omeros Corp, H2 2018 33
Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2018 34
Diabetic Neuropathy - Pipeline by Relief Therapeutics Holding AG, H2 2018 34
Diabetic Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H2 2018 34
Diabetic Neuropathy - Pipeline by Syntrix Biosystems Inc, H2 2018 35
Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2018 35
Diabetic Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H2 2018 36
Diabetic Neuropathy - Pipeline by Yuhan Corp, H2 2018 36
Diabetic Neuropathy - Dormant Projects, H2 2018 104
Diabetic Neuropathy - Discontinued Products, H2 2018 107

  


List Of Figures

Number of Products under Development for Diabetic Neuropathy, H2 2018 11
 Number of Products under Development by Companies, H2 2018 12
 Number of Products by Top 10 Targets, H2 2018 19
 Number of Products by Stage and Top 10 Targets, H2 2018 19
 Number of Products by Top 10 Mechanism of Actions, H2 2018 21
 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 21
 Number of Products by Routes of Administration, H2 2018 23
 Number of Products by Stage and Routes of Administration, H2 2018 23
 Number of Products by Molecule Types, H2 2018 25
 Number of Products by Stage and Molecule Types, H2 2018 25


Global Diabetic Neuropathy Therapeutics Market Research Report 2019-2023

A doctor can usually diagnose diabetic neuropathy by performing a physical exam and carefully reviewing your symptoms and medical history. In the context of China-US trade war and global economic

USD 2850 View Report

Asia Pacific Diabetic Macular Edema Drug Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Asia Pacific Diabetic Macular Edema Drug market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million

USD 3000 View Report

Global Diabetic Neuropathy Therapeutics Market Research Report 2019-2023

A doctor can usually diagnose diabetic neuropathy by performing a physical exam and carefully reviewing your symptoms and medical history. In the context of China-US trade war and global economic

USD 2850 View Report

North America Diabetic Neuropathy Treatment Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The North America Diabetic Neuropathy Treatment market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available